QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial

Cytokinetics (CYTK) Earnings Date, Estimates & Call Transcripts

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free CYTK Stock Alerts
$67.00
-0.93 (-1.37%)
(As of 04:23 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Feb. 27)
-$1.38 Missed By -$0.35
Consensus EPS
(Feb. 27)
-$1.03
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CYTK Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CYTK Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cytokinetics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243($1.33)($0.89)($1.14) 
Q2 20243($1.32)($1.00)($1.18) 
Q3 20243($1.31)($1.13)($1.19) 
Q4 20243($1.37)($1.11)($1.23) 
FY 202412($5.33)($4.13) ($4.74)

CYTK Earnings Date and Information

Cytokinetics last released its earnings results on February 27th, 2024. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by $0.35. The company had revenue of $1.70 million for the quarter, compared to analysts' expectations of $7.62 million. Its revenue for the quarter was down 10.5% compared to the same quarter last year. Cytokinetics has generated ($5.45) earnings per share over the last year (($5.45) diluted earnings per share). Earnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.17) per share. Cytokinetics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Cytokinetics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)		------- 
2/27/2024Q4 2023($1.03)($1.38)($0.35)($1.38)$7.62 million$1.70 million    
11/2/2023Q3 2023($0.72)($1.35)($0.63)($1.35)$24.71 million$0.38 million
8/3/2023Q2 2023($1.23)($1.34)($0.11)($1.34)$5.67 million$0.87 million    
5/4/2023Q1 2023($1.24)($1.38)($0.14)($1.38)$2.50 million$4.60 million    
3/1/2023Q4 2022($1.22)($1.45)($0.23)($1.45)$7.10 million$1.96 million    
11/3/2022Q3 2022($1.19)($1.28)($0.09)($1.04)$2.26 million$2.52 million
8/4/2022Q2 2022($1.04)($0.23)+$0.81($0.23)$3.73 million$88.97 million  
5/4/2022Q1 2022($0.93)($1.02)($0.09)($0.99)$4.72 million$1.15 million    
2/24/2022Q4 2021($0.89)($0.36)+$0.53($0.36)$5.56 million$55.60 million    
11/3/2021Q3 2021($0.75)($0.95)($0.20)($0.95)$5.46 million$5.44 million    
8/5/2021Q2 2021($0.66)($0.86)($0.20)($0.86)$5.68 million$2.84 million    
5/6/2021Q1 2021($0.59)($0.66)($0.07)($0.66)$7.83 million$6.55 million  

Cytokinetics Earnings - Frequently Asked Questions

When is Cytokinetics's earnings date?

Cytokinetics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on CYTK's earnings history.

Did Cytokinetics beat their earnings estimates last quarter?

In the previous quarter, Cytokinetics (NASDAQ:CYTK) missed the analysts' consensus estimate of ($1.03) by $0.35 with a reported earnings per share (EPS) of ($1.38). Learn more on analysts' earnings estimate vs. CYTK's actual earnings.

How can I listen to Cytokinetics's earnings conference call?

The conference call for Cytokinetics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Cytokinetics's conference call transcript?

The conference call transcript for Cytokinetics's latest earnings report can be read online. Read Transcript

How much revenue does Cytokinetics generate each year?

Cytokinetics (NASDAQ:CYTK) has a recorded annual revenue of $7.53 million.

How much profit does Cytokinetics generate each year?

Cytokinetics (NASDAQ:CYTK) has a recorded net income of -$526.24 million. CYTK has generated -$5.45 earnings per share over the last four quarters.

What is Cytokinetics's EPS forecast for next year?

Cytokinetics's earnings are expected to grow from ($4.50) per share to ($3.17) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CYTK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace